Federal and state regulators learned early that a popular marijuana product was causing serious health issues but left it on store shelves for over a year. The delay exposed gaps in oversight of the fast-growing cannabis market and put consumers at continued risk.
Investigators found internal documents showing officials received multiple reports of adverse reactions, including severe vomiting and lung damage, months before any action. Despite clear evidence linking the product to these harms, agencies cited lengthy review processes and industry pushback as reasons for slow response.
The product, sold widely in licensed dispensaries, remained available even after warnings were issued internally. Consumers continued to buy it unaware of the documented dangers, highlighting how regulatory caution often favors business interests over public safety in emerging markets.
Advocates are now calling for faster recall mechanisms and better tracking systems. The case has renewed debate over whether current rules can protect users as marijuana legalization expands across more states.
69.159 SRY